Document 0623
 DOCN  M9590623
 TI    Sense antisense nonantisense. Can these novel antivirals knock HIV
       senseless? Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003.
       800-458-5231 ext. 5023.
 DT    9509
 AU    Chang HE; Mascolini M; Kraus Medical Partners, Clinical Research and
       Development, Los; Angeles, CA.
 SO    J Int Assoc Physicians AIDS Care. 1995 Feb;1(1):11-8. Unique Identifier
       : AIDSLINE AIDS/95700206
 AB    The authors examine the development, theories, research, and use of
       antivirals in the response to HIV infection and AIDS progression and
       address the question of how effective this novel approach may be. The
       article includes discussions that detail the antisense and triple helix
       candidates for HIV and related conditions, the hurdles that exist in the
       development of antisense oligonucleotides, and the way triple helix and
       antisense oligonucleotides disrupt a genetic message.
 DE    AIDS-Related Opportunistic Infections/DRUG THERAPY  Antiviral
       Agents/METABOLISM/PHARMACOLOGY/*THERAPEUTIC USE  Binding Sites  Clinical
       Trials, Phase II  Clinical Trials, Phase III  Cytomegalovirus
       Retinitis/COMPLICATIONS/DRUG THERAPY  DNA, Viral/METABOLISM  HIV/*DRUG
       EFFECTS/GENETICS  HIV Infections/*DRUG THERAPY  Human  Nucleic Acid
       Conformation  Oligonucleotides,
       Antisense/METABOLISM/PHARMACOLOGY/*THERAPEUTIC  USE  RNA,
       Viral/METABOLISM  Thionucleotides/PHARMACOLOGY/THERAPEUTIC USE
       NEWSLETTER ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).